Literature DB >> 2719901

Variability in the elimination of mianserin in elderly patients.

E J Begg1, J R Sharman, J E Kidd, R Sainsbury, D W Clark.   

Abstract

1. Two studies of the elimination of mianserin are reported. 2. In the first study, the oral clearance of mianserin was measured in 15 elderly patients at steady state. In a sub-group of eight patients who completed studies at two different doses there was evidence of enhanced oral clearance at the higher dose. 3. In the second study, the elimination half-life was estimated in 12 patients who were observed to have disproportionately high mianserin concentrations with respect to dose. All had half-lives greater than or equal to 2.5 days with a mean of 6 +/- 2.8 (s.d.) days. In six of the patients the profile of elimination was suggestive of saturable elimination. 4. The sparteine oxidation status was measured in seven of the patients showing slow mianserin elimination. Only one was a 'poor oxidiser' of sparteine, suggesting no concordance with this phenotype. 5. It is concluded that there is marked variability in the elimination of mianserin in elderly patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2719901      PMCID: PMC1379723          DOI: 10.1111/j.1365-2125.1989.tb05392.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  Plasma concentrations of mianserin after single dose and at steady-state in depressed elderly patients.

Authors:  S Dawling; S Ford; P Ariyanayagam; H O'Neal; R R Lewis
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

2.  Influence of age on mianserin pharmacokinetics.

Authors:  A C Altamura; T Melorio; G Invernizzi; R Gomeni
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

3.  Mianserin and blood dyscrasias.

Authors:  H M Clink
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

4.  Plasma levels of the antidepressant drug mianserin: relevance to clinical pharmacology and therapy.

Authors:  F van der Veen; J J de Ridder; J Vink; H P Wijnand
Journal:  Ther Drug Monit       Date:  1980       Impact factor: 3.681

5.  Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.

Authors:  M Eichelbaum; L Bertilsson; J Säwe; C Zekorn
Journal:  Clin Pharmacol Ther       Date:  1982-02       Impact factor: 6.875

6.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

7.  Mianserin kinetics in depressed patients.

Authors:  P D Hrdina; Y D Lapierre; B McIntosh; L K Oyewumi
Journal:  Clin Pharmacol Ther       Date:  1983-06       Impact factor: 6.875

8.  The pharmacokinetics of mianserin.

Authors:  M Shami; H L Elliott; A W Kelman; B Whiting
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

9.  The potential therapeutic role of the enantiomers and metabolites of mianserin.

Authors:  R M Pinder; A M Van Delft
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

10.  Anticholinergic and blood pressure effects of mianserin, amitriptyline and placebo.

Authors:  H Kopera
Journal:  Br J Clin Pharmacol       Date:  1978       Impact factor: 4.335

View more
  5 in total

Review 1.  Antidepressants in the elderly: challenges for study design and their interpretation.

Authors:  C Parikh
Journal:  Br J Clin Pharmacol       Date:  2000-06       Impact factor: 4.335

Review 2.  Adverse effects of antidepressants in the elderly.

Authors:  L Nolan; K O'Malley
Journal:  Drugs Aging       Date:  1992 Sep-Oct       Impact factor: 3.923

3.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 4.  Choosing appropriate antidepressant therapy in the elderly. A risk-benefit assessment of available agents.

Authors:  A J Flint
Journal:  Drugs Aging       Date:  1998-10       Impact factor: 3.923

Review 5.  Pharmacokinetic optimisation of therapy with newer antidepressants.

Authors:  P J Goodnick
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.